Compare ATS & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATS | SRPT |
|---|---|---|
| Founded | 1978 | 1980 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2023 | 1997 |
| Metric | ATS | SRPT |
|---|---|---|
| Price | $28.04 | $21.27 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 29 |
| Target Price | N/A | ★ $26.23 |
| AVG Volume (30 Days) | 83.5K | ★ 2.9M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,930,283,080.00 | ★ $2,413,715,000.00 |
| Revenue This Year | $16.92 | $13.72 |
| Revenue Next Year | $5.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 47.15 |
| 52 Week Low | $20.90 | $10.42 |
| 52 Week High | $32.73 | $129.84 |
| Indicator | ATS | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | 50.58 |
| Support Level | $27.32 | $21.36 |
| Resistance Level | $28.63 | $22.52 |
| Average True Range (ATR) | 0.82 | 0.95 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 65.60 | 40.84 |
ATS Corp is a Canada-based company that provides automation systems. The company designs and builds customized automated manufacturing and testing systems for customers, and provides pre- and post-automation services. The company's products comprise conveyor systems, automated electrified monorails, tray handlers, laser systems, and other hardware and software products. The company also provides pre-automation solutions, including strategic direction and planning services, as well as aftermarket support. The company's clients come from the life sciences, food and beverage transportation, consumer products and electronics, and energy sectors. The company generates the majority of its sales from the North American and European markets.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.